The use of α-adrenoceptor antagonists in the phamacological management of benign prostatic hypertrophy: An overview

Pharmacological Research

Volumn 33, Issue 3, 1996, Pages 145-160

  Hieble, J Paul ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alfuzosin; Doxazosin; Phenoxybenzamine; Prazosin; Stromal smooth muscle; Tamsulosin; Terazosin; Urethral obstruction; Uroselectivity; (1a) adrenoceptors; (1L) adrenoceptors; 1 adrenoceptors

Indexed keywords

8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIANDROGEN; ATIPAMEZOLE; BUNAZOSIN; CYPROTERONE; DOXAZOSIN; EPRISTERIDE; FINASTERIDE; GI 231818; INDORAMIN; MOXISYLYTE; PHENOXYBENZAMINE; PHENTOLAMINE; PLANT EXTRACT; PRAZOSIN; RECEPTOR SUBTYPE; SL 890591; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; ECONOMIC ASPECT; ELECTROSTIMULATION; HUMAN; HYPERPLASIA; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; LASSITUDE; LIFESPAN; LIGAND BINDING; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVIEW; SIDE EFFECT; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE TONE; SYNCOPE; TISSUE GROWTH; URETHRA STENOSIS; VERTIGO;

EID: 0030109784     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0022     Document Type: Article

References (159)

1. 1. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 495-507.
2. 2. Randall A, Hinman F Jr. Surgical anatomy of the prostatic lobes. In: Hinman F Jr, ed. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983: 672-7.
3. 3. Lytton B. Interracial incidence of benign prostatic hypertrophy. In: Hinman F Jr, ed. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983: 22-6.
4. 4. McNeal JE. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin North Am 1990; 17: 477-86.
5. 5. Tannenbaum SI, Paulson DF. Effect of hormones on established prostatic hypertrophy. In: Hinman F Jr, ed. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983: 256-61.
6. 6. Bartsch G, Muller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostate hyperplasia. J Urol 1979; 122: 487-91.
7. 7. McNeal JE. Relationship of the origin of benign prostatic hypertrophy to prostatic structure of man and other mammals. In: Hinman F Jr, ed. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983: 152-66.
8. 8. Caine M, Raz S, Ziegler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193-202.
9. 9. Belis JA, Longhurst PA, Westfall DP. Neurogenic activity of smooth muscle from hyperplastic human prostates. Am Coll Surg Surg Forum 1983; 34: 656-9.
10. 10. Hedlund H, Andersson KE, Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985; 134: 1291-7.
11. 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. Br J Pharmacol 1995; 115: 142-6.
12. 12. Furuya S, Kumamoto E, Yokoyama T, Tsukamoto T, Izumi T, Abiko Y. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836-9.
13. 13. Hieble JP, Caine M, Zalaznik E. In vitro characterization of the alpha-adrenoceptors in human prostate. Eur J Pharmacol 1985; 107: 111-7.
14. 1C-) adrenoceptor subtype. Br J Pharmacol 1995; 115: 781-6.
15. 1-antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther 1996; in press.
16. 16. Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 641-9.
17. 1 adrenergic receptors in human benign prostatic hyperplasia. J Urol 1984; 132: 1226-9.
18. 18. Neri RC, Casmer C, Zeman WV, Fielder F, Tabachnick IIA. Effects of an anti-androgen, cyproterone acetate, on canine prostatic hyperplasia. Endocrinology 1968; 82: 311-7.
19. 19. Scott WW, Wade JC. Medical treatment of benign nodular prostatic hypertrophy with cyproterone acetate. J Urol 1969; 101: 81-5.
20. 20. Baulieu EE, Lasnitzki I, Robel P. Metabolism of testosterone and action of metabolites on prostate glands grown in organ culture. Nature 1968; 219: 1155-7.
21. 21. Siiteri PK, Wilson JD. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 1970; 49: 1737-45.
22. 22. Paubert-Braquet M, Janssen DH, Servent N, Serikoff A, Schulman C, Monge MC, Kiss R. Permixon inhibits b-FGF and EGF-induced proliferation of human prostate organotypic cell lines. Pharmacol Res 1995; 31 (Suppl.): 69.
23. 23. Delos S, Carsol J-L, Ghazarossian E, Raynaud J-P, Martin P-M. Testosterone metabolism in primary culture of human prostate epithelia cells and fibroblasts. J Steroid Biochem Mol Biol 1995; 55: 375-83.
24. 24. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 461-2.
25. 25. Caine M. Clinical experience with alpha-adrenergic antagonist in benign prostatic hypertrophy. Fed Proc 1986; 45: 2604-8.
26. 26. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986; 136: 1-4.
27. 1-adrenergic receptor. Proc Natl Acad Sci USA 1988; 85: 7159-63.
28. 1-adrenergic receptor subtype. J Biol Chem 1990; 265: 8183-9.
29. 29. Lomasney JW, Cotecchia S, Lefkowitz RJ, Caron MG. Molecular biology of α-adrenergic receptors: implications for receptor classification and for structure-function relationships. Biochim Biophys Acta 1991; 1095: 127-39.
30. 1D-adrenergic receptor cDNA. Mol Pharmacol 1991; 40: 876-83.
31. 1-adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-51.
32. 1C-adrenoceptor in human prostate: cloning functional expression, and localization to specific prostatic cell types. Br J Pharmacol 1995; 115: 1475-85.
33. 33. Flavahan NA, Vanhoutte PM. α-adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol Sci 1986; 7: 347-9.
34. 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol 1990; 99: 197-201.
35. 35. Raz S, Ziegler M, Caine M. Pharmacological receptors in the prostate. Br J Urol 1973; 45: 663-7.
36. 36. Shapiro A, Mazouz B, Caine M. The alpha-adrenergic blocking effect of prazosin on the human prostate. Urol Res 1981; 9: 17-20.
37. 37. Longhurst PA, Belis JA, Westfall DP. Contractile response of human prostatic strips. Fed Proc 1983; 42: 735.
38. 38. Kitada S, Kumazawa J. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J Urol 1987; 138: 158-60.
39. 1A-adrenergic receptors in the isolated human prostate. Pharmacol Commun 1994; 4(3): 181-8.
40. 1C subtype. Mol Pharmacol 1994; 45: 703-8.
41. 1C-adrenoceptor: functional characterization in prostate. Br J Pharmacol 1992; 112: 59P.
42. 1-adrenoceptor antagonist, on human hyperplastic prostates. Eur J Pharmacol 1994; 252: 29-34.
43. 43. Gup DI, Shapiro E, Baumann M, Lepor H. Contractile properties of human prostate adrenomas and the development of infravesical obstruction. Prostate 1989; 15: 105.
44. 44. Moriyama N, Miyata N, Yamaura H, Yamazaki R, Tsuchida K, Kurimoto S, Nagase Y, Ishida Y, Kawabe K. Multidirectional contraction of human hypertrophied prostate. Gen Pharmacol 1994; 25(7): 1459-64.
45. 45. Hieble JP, Boyce AJ, Caine M. Comparison of the alpha-adrenoceptor characteristics in human and canine prostate.Fed Proc 1986; 45: 2609-14.
46. 46. Kunisawa Y, Kawabe K, Nijinia T, Honda K, Takenaka T. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra. J Urol 1985; 134: 396-8.
47. 47. Medgett IC, McCulloch MW, Rand MJ. Partial agonist action of clonidine on prejunctional and postjunctional alpha-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 1978; 304: 215-21.
48. 2-adrenoceptor blockade by SK & F 86466. In vitro characterization of receptor selectivity. J Pharmacol Exp Ther 1996; 236: 90-6.
49. 2+ in smooth muscle. Nature 1987; 329: 333-5.
50. 1-adrenergic receptor subtypes distinguished by chloroethylclonidine and WB 4101. Mol Pharmacol 1988; 33: 509-14.
51. 50. Muramatsu I, Yamanaka K, Kigoshi S. Pharmacological profile of the novel α-adrenoceptor antagonist KT-611 (Naftopidil). Jpn J Pharmacol 1991; 55: 391-8.
52. 1-adrenocepts. Pharmacol Commun 1995; 6: 23-8.
53. 1-adrenergic receptor subtypes in rat brain: a re-evaluation of 3H-WB4101 and 3H-prazosin binding. Mol Pharmacol 1986; 29: 321-30.
54. 53. Hieble JP, McCafferty GP, Naselsky DP, Bergsma DJ, Ruffolo RR Jr. Recent progress in the pharmacotherapy of disease of the lower urinary tract. Eur J Med Chem 1995; 30(Suppl.): 269s-298s.
55. 54. Chapple CR, Crowe R, Gilpin SA, Gosling J, Burnstock G. The innervation of the human prostate gland - the changes associated with benign enlargement. J Urol 1991; 146: 1637-44.
56. 1C-adrenergic receptor: Characterisation of signal transduction pathways and mammalian tissue heterogeneity. Mol Pharmacol 1991; 40: 619-26.
57. 1-adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol Sci. 1994; 15: 167-70.
58. 1A subtype. Mol Pharmacol 1994; 46: 414-22.
59. 1A-subtype? FASEB J 1994; 8: A353.
60. 59. Forray C, Chiu G, Wetzel JJ, Bard JA, Weinshank RL, Branchek TA, Hartig P, Gluchowski C. Effects of novel alpha-1C adrenergic receptor antagonists on the contraction of human prostate smooth muscle. J Urol 1994; 151(5): 267A.
61. 1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 April 4, 1995.
62. 1-adrenoceptors in prostate of man: implications for adrenoceptor classification. Mol Pharmacol 1996; 49: 209-15.
63. 62. Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I. Alpha-adrenoceptor subtypes in the human prostate. Br J Urol 1994; 74: 585-9.
64. 1A adrenoceptor antagonist, RS 17053. Br J Pharmacol 1995; 114: 24P.
65. 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol 1994; 74: 572-8.
66. 65. Yamanaka N, Yamaguchi O, Kameoka H, Fukaya Y, Yokoto T, Shiraiwa Y. Effect of KT-611 (naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction. Acta Urol Jpn 1991; 37: 1759-72.
67. 1-adrenoceptor subtypes in dog prostate. Jpn J Pharmacol 1992; 58(Suppl. II): 174.
68. 67. James S, Chapple CR, Phillips MI, Greengrass PM, Davey MJ, Turner-Warwick RT, Milroy EJG, Burnstock G. Autoradiographic analysis of alpha-adrenoceptors and muscarine cholinergic receptors in the hyperplastic human prostate. J Urol 1989; 142: 438-44.
69. 1-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 1994; 21: 405-11.
70. 1 adrenoceptors in human prostates. J Urol 1991; 146: 877-80.
71. 1-adrenoceptor antagonists to prostatic α-adrenoceptors in benign prostatic hypertrophy. Life Sci 1991; 50: 127-35.
72. 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol 1993; 249: 307-15.
73. 1-adrenoceptor subtypes present in the human prostate. Life Sci 1994; 54: 1595-605.
74. 1 adrenoceptor subtypes in the human prostate. J Urol 1993; 149: 640.
75. 74. Goetz AS, Lutz MW, Rimele TJ, Saussy DL. Characterization of alpha-1 adrenoceptor subtype in human and canine prostate membranes. J Pharmacol Exp Ther 1994; 271: 1228-33.
76. 1-selective antagonist. Acta Histochem Cytochem 1994; 27(3): 219-25.
77. 1-adrenoceptors in human prostate. Jpn J Pharmacol 1993; 61(Suppl. 1): 340P.
78. 77. Chapple CR, Aubry ML, James S, Greengrass PM, Burnstock G, Turner-Warwick RT, Milroy EJ, Davey MJ. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol 1989; 63: 487.
79. 1-adrenoceptors in human prostate: special reference to zonal difference. J Urol 1991; 146: 887-90.
80. 79. Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue sections. J Urol 1993; 150: 2002-6.
81. 1A-adrenoceptor in the human prostate. J Urol 1995; 154: 2096-9.
82. 1-adrenoceptor subtypes in the human prostate and internal iliac artery - autoradiographic analysis using imaging plates and BAS3000. J Urol 1994; 151(5): 298A.
83. 2 adrenergic receptor. J Urol 1985; 133: 133A.
84. 2 receptors in serotonin-induced contraction of rat prostate: autoradiographical and functional studies. Eur. J Pharmacol 1995; 273: 7-14.
85. 1A type. Jpn J Pharmacol 1993; 62: 297-304.
86. 2-antagonists on the hormonally stimulated porstate. J Urol 1994; 151: 510A.
87. 3H-prazosin. Neurourol Urodynam 1991; 10: 257-66.
88. 87. Sulpizio AC, Naselsky DP, Hieble JP. Further characterization of the a1-adrenoceptors of canine prostate. FASEB J 1992; 6: A1021.
89. 88. Somers WJ, Felsen D, Chou TC, Marion DN, Chernesky CE, Darracott-Vaughan E. An in vivo evaluation of alpha adrenergic receptors in canine prostate. J Urol 1989; 141: 1230-3.
90. 89. Brune MF, Buckner SA, Polakowski J, Kerwin JF Jr, Hancock AA. Pharmacological antagonism of α-adrenergic agonist induced increases in canine intraurethral pressure in vivo. Drug Dev Res 1995; 34: 267-75.
91. 1-adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetised dog. Urology 1994; 44: 52-7.
92. 1-antagonist selective for the lower urinary tract: in vivo studies. Neurol Urodyn 1994; 13: 471-3.
93. 1-adrenoceptors: subtype and organ-selectivity of different agents. In: Giardina D, Piergentili A, Pigini A, eds. Perspective in receptor research. Proceedings of the Tenth Camerino-Noodwijkerout Symposium, September 1995.
94. 1-antagonist selective for the lower urinary tract: in vitro studies. Neurol Urodyn 1994; 13: 473-4.
95. 94. Broderick GA, Longhurst PA, Juniewicz PE, Wein AJ, Levin RM. A novel canine model of partial outlet obstruction secondary to prostatic hypertrophy. World J Urol 1994; 12: 245-8.
96. 95. Karr JP, Kim U, Murphy GP, Sandberg AA. Benign prostatic hyperplasia in the baboon. In: eds. Kimbal FA, Buhl AE, Carter DB, New approaches to the study of benign prostatic hyperplasia. New York: AR Liss, 1984. 257-89.
97. 96. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-63.
98. 97. Boreham PF, Braithwaite P, Milewski P, Pearson H. Alpha-adrenergic blockers in prostatism. Br J Surg 1977; 64: 756-7.
99. 98. Caine M, Perlberg S, Meretyk S. A placebo-controlled double blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551-4.
100. 99. Gerstenberg T, Blaadjerg J, Nielsen ML, Clausen S. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. Invest Urol 1980; 18: 29-31.
101. 100. Abrams PH, Shah PJR, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982; 54: 527-30.
102. 101. Abrams PH, Hollister P, Lawrence J, Doyle PT, Sherwood T, Whitaker RH. Preliminary note (Phenoxybenzamine in BPH). Br J Urol 1982; 54: 530.
103. 102. Brooks ME, Sidi AA, Hanani Y, Braf ZF. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. Urology 1983; 21: 474-8.
104. 103. Caine M. Phenoxybenzamine in benign prostatic hypertrophy. Urology 1983; 22: 351-2.
105. 104. Griffiths DJ, Schroeder FH. Phenoxybenzamine in prostatic obstruction. Urol Int 1984; 39: 241-2.
106. 105. Rohner TJ, Hannigan JD, Sanford EJ. Altered in vitro adrenergic responses of dog detrusor muscle after chronic bladder outlet obstruction. Urology 1978; 11: 357-61.
107. 106. Perlberg S, Caine M. Adrenergic response of bladder muscle in prostatic obstruction: its relation to detrusor instability. Urology 1982; 20: 524-7.
108. 107. Lardennois B, Khansa AE, Amory JP, Coulon JM, Lemaire P. La phenoxybenzamine en pathologie prostatigue. Ann Urol 1981; 15: 399-402.
109. 108. Caine M, Perlberg S. Dynamics of acute retention in prostatic patient and role of adrenergic receptors. Urology 1977; 9: 399-403.
110. 109. Reuther K, Aagaard J. Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers. Urol Int 1984; 39: 114-59.
111. 110. Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate Suppl 1990; 3: 75-84.
112. 111. Andersson KE, Ek A, Hedlund H, Mattiasson A. Effects of prazosin on isolated human urethra and in patients with lower motor neuron lesions. Invest Urol 1981; 19: 39-42.
113. 112. Okamura K, Takamatsu T, Koyanagi T. Management of chronic spinal cord injury patients with prazosin. Jpn J Urol 1983; 74: 1621-6.
114. 113. Thien TH, Delaere KP, Debruyne FMJ, Koene RAP. Urinary incontinence caused by prazosin. Br Med J 1978; 1: 622-3.
115. 114. Takita T, Otani T, Kondo A, Mitsuya H. Urodynamic study of lower urinary tract. XII. The effect of prazosin hydrochloride in the treatment of prostatic obstruction. Jpn J Urol 1983; 74: 1-14.
116. 115. Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275-8.
117. 116. Martorana G, Gilberti C, Damonte P, Ciprandi G, Dirienzo W, Giuliani L. The effect of prazosin in benign prostatic hypertrophy, a placebo controlled double-blind study. IRCS Med Sci 1984; 12: 11-2.
118. 117. Kirby RS, Coppinger SWC, Corcoran MO et al. Prazosin in benign prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 60: 136-42.
119. 118. Yamamaguchi O, Shiraiwa Y, Kobayashi M, Yokota T, Ohinata M. Clinical evaluation of effects of prazosin with benign prostatic obstruction: a double blind, multi-international paraprost control study. Urol Internationls 1990; 15(Suppl. 1): 40-6.
120. 1-adrenoceptor antagonist. Pharmacol Commun 1995; 6: 79-86.
121. 120. Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology 1988; 32(Suppl. 6): 27-31.
122. 121. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74.
123. 122. Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary AV, et al. Terazosin in the treatment of benign prostatic hyperplasia: a multicenter, placebo control trial. Er J Urol 1992; 70(1): 17-21.
124. 123. Fabrisius PG, Hannaford JM. Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. Br J Urol 1992; 70(Suppl. 1): 10-16.
125. 124. Lepor H, Meretyk S, Knapp-Maloney G. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J Urol 1992; 147: 1554-7.
126. 125. Park Y-C, Nishioka T, Kurita T, Nagai N, Kataoka K, Arai Y, Tomoyohis T, Hayashida H, Inoue H, Kitagawa Y, Miyazaki S, Hasegawa F, Demura A, Yasumoto R, Yohishara H, Mawkawa M, Tanaka H, Kawamura M, Ihara H, Arima M, Ikoma F, Kuroda J, Yasuno H, Miyazaki J, Kamidono S, Hirooka K, Umezu K. A multicenter, fixed-flexible dose study of terazosin hydro chloride in the treatment of symptomatic benign prostatic hypertrophy. Acta Urol Jpn 1992; 38: 857-68.
127. 126. Lepor H, Henry D, Laddu AR. The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate 1991; 18: 345-55.
128. 127. Hill SJ, Lawrence SL, Lepor H. New use of alpha blockers: benign prostatic hyperplasia. Am Fam Physician 1994; 49(8): 1885-8.
129. 128. Kirby RS. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. Br J Clin Pract 1994; (Suppl. 74): 23-8.
130. 129. Christensen MM, Bendix-Holme JB, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, Husted SE. Doxazosin treatment in patients with prostatic obstruction: a double blind placebo controlled study. Scand J Urol Nephrol 1993; 27: 39-44.
131. 130. Chapple CR, Carter P, Christmas TJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6.
132. 131. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9.
133. 132. Kaplan SA, Soldo KA, Olsson CA. Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study. Urology 1994; 44(3): 348-52.
134. 133. Kaplan SA, Meade-D'Alissera P, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46: 512-7.
135. 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 1993; 109: 1282-9.
136. 135. Jardin A. Efficacy of an alpha-blocker, alfuzosine on disturbances of micturition in patients with prostatic adenoma. Intemediate results of a European multicenter study. Ann Urol 1988; 22: 333-40.
137. 136. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, the BPHALF Group. Alfuzosin for treatment of benign hypertrophy. Lancet 1991: 337: 1457-61.
138. 137. Hansen BJ, Nording J, Mensink HJA, Walter S, Meyhoff HH, the ALFECH Study Group. Alfuzosin in the treatment of benign prostatic hyperplasia: effects of symptoms scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol 1994; 157(Suppl.): 169-76.
139. 138. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P, the BPHALF Group. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. Br J Urol 1994; 74: 579-84.
140. 139. Lukacs B, McCarthy C, Grange JC. Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1 adrenergic blocker, alfuzosin-QOL BPH Study Group in General Practice. Eur Urol 1993; 24(Suppl.): 34-40.
141. 140. Wilde MI, Fitton A, McTavish D. Alfuzosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993; 45(3): 410-29.
142. 141. Buzelin JM, Hebert M, Blondin P, the PRAZALF Group. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72: 922-7.
143. 142. Buzelin JM, Geffriaud-Ricouard C, Delauche-Cavallier MC, Weber F, Proffit O, Roth S. A double-blind placebo-controlled trial of the efficacy and safety of sustained-release alfuzosin in symptomatic benign prostatic hyperplasia. J Urol 1995; 153(Suppl.): 274A.
144. 143. Teillac P, Delauche-Cavallier MC, Attali P, the DUALF Group. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Pharmacol Urol 1992; 70: 58-64.
145. 144. Gilberti C, Damonte P, Michelotti P, Martorana G. The effect of thymoxamine in benign prostatic hypertrophy: a double blind cross-over study. IRCS Med Sci 1984; 12: 591.
146. 145. Ronchi F, Margonato A, Ceccardi R, Rigatti P, Rossine BM. Symptomatic treatment of benign prostatic obstruction with nicergoline: a placebo controlled clinical study and urodynamic evaluation. Urol Res 1982; 10: 131-4.
147. 146. Fujita T, Ohshima S, Asano H, Ono Y, Kinukawa T, Kato N, Hirabayashi S. The evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasia. Acta Urol Jpn 1992; 38: 613-21.
148. 147. Kumamoto Y, Tsukamoto T, Takagi Y, Furya S, Yokoyama E, Takatsuki A, Tamiya T, Miyamoto S, Aoyama T, Honma A. Study of the efficacy of oxendolone (an antiandrogen) and bunazosin hydrochloride, an α-adrenergic blocker in the treatment of prostatism: three-group comparative study of oxendolone and bunazosin hydrochloride administered singly and in combination. Acta Urol Jpn 1987; 33(11): 1921-41.
149. 148. Weidinger G. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. Arzneim-Forsch/Drug Res 1995; 45(11): 1166-71.
150. 149. Lepor H. Clinical evaluation of tamsulosin, a prostate selective alpha 1C antagonist. J Urol 1995; 153(Suppl.): 274A.
151. 150. Scott MA, Abrams PH. Indoramin in benign prostatic hypertrophy: a placebo controlled trial. Br J Urol 1991; 67: 499-501.
152. 151. Iacovou JW, Dunn M. Indoramin: An effective new drug in the management of bladder outlet obstruction. Br J Urol 1987; 60: 526-32.
153. 152. Chow W, Hahn D, Sandhu D, et al. Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br J Urol 1990; 65: 36-8.
154. 1-adrenoceptors and native tissue. Mol Pharmacol 1995; 48: 250-8.
155. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-12.
156. 155. Abrams PH, Schulman CC, Vaage S. The efficacy and safety of 0.4 mg tamsulosin once daily in symptomatic BPH. J Urol 1995; 153(Suppl.): 274A.
157. 1-adrenoceptors: pharmacological classification and newer therapeutic applications. Proc West Pharmacol Soc 1995; 38: 121-6.
158. 1-adrenoceptor subtype affinities. Br J Pharmacol 1995; 116: 209P.
159. 1-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur J Med Chem 1995; 30(Suppl): 299s-310s.